We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · May 12, 2021

Talimogene Laherparepvec and Immune-Cell Populations in Non-Injected Lesions in Stage IIIB–IVM1c Melanoma

Journal for immunotherapy of cancer


Additional Info

Journal for immunotherapy of cancer
Talimogene Laherparepvec Upregulates Immune-Cell Populations in Non-Injected Lesions: Findings From a Phase II, Multicenter, Open-Label Study in Patients With Stage IIIB-IVM1c Melanoma
J Immunother Cancer 2021 Mar 01;9(3)e001621, J Malvehy, I Samoylenko, D Schadendorf, R Gutzmer, JJ Grob, JJ Sacco, KS Gorski, A Anderson, CA Pickett, K Liu, H Gogas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading